The Journal of Precision Medicine
PMLS
PMLS
BMS
BMS

Agilent Announces New SureSelect Human All Exon V8

2021-06-04T13:53:57-05:00June 4th, 2021|

Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 – a new exome design that provides comprehensive content and up-to-date coverage of protein-coding regions from RefSeq, CCDS, and GENCODE. It also covers the TERT promoter and hard-to-capture exons that are omitted by other exomes on the market. The [...]

New Research from Caris Life Sciences Finds Immunotherapy Resistance in Leiomyosarcoma

2021-06-04T13:36:10-05:00June 4th, 2021|

Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, to present findings that provide a deeper understanding of how immunotherapies (IO) affect leiomyosarcoma (LMS), a rare cancer that affects smooth muscle tissue, through the use of whole exome and whole transcriptome sequencing. These [...]

Labcorp to Introduce Combined Oncology Offering at 2021 ASCO® Annual Meeting

2021-06-04T13:31:37-05:00June 4th, 2021|

Labcorp (NYSE: LH), a leading global life sciences company, today announced the introduction of its combined Labcorp oncology platform at the virtual 2021 American Society of Clinical Oncology (ASCO®) Annual Meeting held June 4-8. Labcorp’s oncology platform brings together the company’s leadership in diagnostic testing with its comprehensive drug development services, delivering targeted solutions [...]

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

2021-06-04T13:27:57-05:00June 4th, 2021|

Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with Tabrecta® (capmatinib) in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14)1-3. Data from the ongoing, pivotal, multi-cohort Phase II GEOMETRY [...]

Bristol Myers Squibb Presents Data from CheckMate -648

2021-06-04T13:24:13-05:00June 4th, 2021|

Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -648 trial, in which two Opdivo-based treatment combinations — Opdivo (nivolumab)plus chemotherapy and Opdivo plus Yervoy (ipilimumab) —demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to chemotherapy at the pre-specified interim analysis in patients with unresectable advanced or [...]

Go to Top